Insider filing
Traded Nov 17, 2025 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 7, 2025 · Filed Nov 8, 2025
The CFO of Lenz Therapeutics paid $50K out of pocket for Lenz Therapeutics shares. 1 other person at Lenz Therapeutics bought some too, in the same month. Shares held went up 68% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$49,563
Shares × reported transaction price
$25K–$100K
+67.9%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
2 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
2 days after results of Nov 5, 2025, 61 days before results of Jan 7, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $22.97 on Nov 7, 2025, 25% above its 52-week low and 53% below its high, after a 45% drop over the previous 30 trading days
52-week range $18.32 (Apr 8, 2025) to $49.05 (Oct 1, 2025), 15% of the way up, from 250 adjusted closes. 30 trading days earlier: $42.03 on Sep 26, 2025. Describes the past only, not a forecast
RSI 24, 26% under its 200-day average, 40% under its 50-day average, 53% below the 52-week high, 20-day volatility 109% a year, against the S&P 500: −50 points over 1 month, −46 points over 3 months, −32 points over 6 months
From the adjusted closes up to Nov 7, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
The first open-market purchase by any LENZ insider since May 2024
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +10.8% | −2.3% | +13.1% |
| 30 days | +8.0% | +0.9% | +7.1% |
| 90 days | −39.6% | +1.8% | −41.4% |
| 180 days | −56.9% | +8.5% | −65.4% |
| 365 days | −82.3% | +10.1% | −92.4% |
Past results only. Not a forecast.
Insider filing
Traded Nov 17, 2025 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Shawn Olsson (Chief Commercial Officer) sold ~$108K of Lenz Therapeutics
Planned saleShawn Olsson (Chief Commercial Officer) sold ~$153K of Lenz Therapeutics
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.